title: Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
abstract: BACKGROUND
  Ovarian metastases from gastrointestinal tumours frequently lead to locoregional complications and undermine quality of life. The chemosensitivity of ovarian metastases from gastric cancer is unknown.
  
  
  OBJECTIVE
  To evaluate the efficacy of modern chemotherapy regimens in first-line treatment for patients with ovarian metastases from gastric cancer.
  
  
  METHODS
  All consecutive patients with ovarian metastases from gastric cancer who received at least one cycle of chemotherapy were included in this retrospective study.
  
  
  RESULTS
  Thirty-five patients were included (median age, 50.5 years; synchronous ovarian metastases, 60%). Seventeen patients (48.6%) underwent oophorectomy. Patients were treated with first-line chemotherapy based on platinum (n=14), irinotecan (n=8), taxane plus platinum (n=4) or epirubicin plus platinum (n=9). The median PFS and OS were 6.8 and 18.8 months, respectively. The objective response rate (ORR) for extra-ovarian (13.6%) and ovarian (20.9%) metastatic sites was not significantly different (p=0.55). There was no significant difference in terms of ORR on ovarian metastatic site according to the first-line chemotherapy (p=0.21). In multivariate analysis, oophorectomy was an independent prognostic factor for OS (p<0.01).
  
  
  CONCLUSIONS
  This study suggests that ovarian metastases from gastric cancer are not more resistant than extra-ovarian metastases, and that oophorectomy is an independent prognostic factor significantly linked to OS. Prospective studies are needed to confirm these results.
authors.affiliation: Gastroenterology and Digestive Oncology Department, Cochin University Hospital, APHP, Paris, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Brieau
authors.affiliation: Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Auzolle
authors.affiliation: Methodology and Quality of Life in Oncology Unit (EA 3181), Besançon University Hospital, Besançon, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Pozet
authors.affiliation: Department of Gastroenterology, Poitiers University Hospital, Poitiers, France; Poitiers University, Laboratory "Inflammation, Tissus Epithéliaux et Cytokines EA 4331", Poitiers, France.
authors.forename: David
authors.initials: D
authors.lastname: Tougeron
authors.affiliation: Department of Hepato-Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.affiliation: Department of Hepato-Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Soibinet
authors.affiliation: Gastroenterology and Digestive Oncology Department, Cochin University Hospital, APHP, Paris, France; Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France.
authors.forename: Romain
authors.initials: R
authors.lastname: Coriat
authors.affiliation: Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Prieux
authors.affiliation: Department of Gastroenterology, Tours University Hospital, Tours, France; Francois Rabelais University, Faculty of Medicine, Tours, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Lecomte
authors.affiliation: Gastroenterology and Digestive Oncology, Bichat Hospital, APHP, Paris, France.
authors.forename: Gael
authors.initials: G
authors.lastname: Goujon
authors.affiliation: Department of Gastroenterology and Digestive Oncology, Antoine Béclère Hospital, Clamart, APHP, France.
authors.forename: Lysiane
authors.initials: L
authors.lastname: Marthey
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France; Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, APHP, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
authors.affiliation: Methodology and Quality of Life in Oncology Unit (EA 3181), Besançon University Hospital, Besançon, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Bonnetain
authors.affiliation: Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France; Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, APHP, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
authors.affiliation: Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France; Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, APHP, Paris, France. Electronic address: aziz.zaanan@aphp.fr.
authors.forename: Aziz
authors.initials: A
authors.lastname: Zaanan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005602:France; D006801:Humans; D000077146:Irinotecan; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D010052:Ovariectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D043823:Taxoids / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D015251:Epirubicin; D000077146:Irinotecan; D002945:Cisplatin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Chemosensitivity; Gastric cancer; Oophorectomy; Ovarian metastases